Overview

Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)

Status:
Terminated
Trial end date:
2019-03-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety and efficacy of EMA401 compared to placebo in patients with painful diabetic neuropathy (PDN).
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Angiotensin II Type 2 Receptor Blockers